gMS-Classifier1 does not predict disability progression in multiple sclerosis
Date received: 24 July 2018; accepted: 9 August 2018 Several clinical, immunological and radiological biomarkers have been shown to predict the disease course of multiple sclerosis (MS). [1] [2] [3] [4] [5] One potential serum marker is the gMS-Classifier1, which is composed of IgM anti-Glc antibodies, namely anti-GAGA 2,3,4 and 6. Previous work demonstrated that the gMS-Classifier1 could not predict early conversion to clinically definite MS in a cohort of clinically isolated syndrome (CIS) patients, but predicted Expanded Disability Status Scale (EDSS) progression. Significance, however, was dependent on covariates, and confirmation in an independent study was required. 3 The aim of this study was to test if the gMS-Classifier1 could predict early disability progression in a large multicenter cohort of patients with CIS or relapse-onset MS.
Blood samples and clinical data were prospectively collected in four MS centers between 1993 and 2007: The Ottawa Hospital, Ottawa, Canada; Amsterdam University Medical Centers, the Netherlands; UMass Memorial Medical Center, Worcester, USA; and Hospital Ramón y Cajal, Madrid, Spain. Patients had a diagnosis of CIS (n = 118) or relapsing remitting multiple sclerosis (RRMS; n = 240) at study onset. Age at blood sampling was between 18 and 50 years. Serum samples were stored frozen <-70°C until assayed.
Baseline (EDSS) was performed within 6 months of blood sampling and was repeated during patient routine visits. Disability progression was defined as a sustained (⩾6 months) progression of at least 1.0 EDSS point over the baseline EDSS and progression to an EDSS score of 3.0 or higher.
Mean follow-up was 94 months.
In 2012, frozen serum samples were shipped to Glycominds Inc Lab (Simi Valley, CA, USA) for testing for anti-glycan antibodies as described before. 3 If one of the antibodies was above the predefined cut-off (anti-GAGA2 >148.8 EIA units, anti-GAGA3 >164.6 EIA units, anti-GAGA4 >133.6 EIA units, and anti-GAGA6 >168.1 EIA units), patients were considered positive for the gMS-Classifier1. There were no significant differences for the key variables gMS-Classifier1 and EDSS progression between the four centers.
Of the 358 patients, 44 (12. Here, we present the results of a large cohort of patients from different centers from two continents, showing no statistical differences between gMS-Classifier1 positive and negative patients, convincingly indicating that the gMS-Classifier1 does not predict disability progression in MS.
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